STARLIMS, backed by Francisco Partners, announced on August 22 its acquisition of Labstep for an undisclosed price. According to data captured in the LevinPro HC database, this acquisition represents the 92nd Laboratories, MRI and Dialysis transaction of 2023
Labstep is a modern R&D cloud platform helping customers unlock the power of real-time data. Found in more than 900 universities and more than 65 companies worldwide, Labstep’s Electronic Laboratory Notebook (ELN) platform streamlines laboratory work, delivers real-time data capture and collaboration and enhances data integrity.
STARLIMS provides enterprise informatics solutions and is committed to providing quality products and services to more than 1,100 customers across the globe. Found in more than 2,000 laboratories, STARLIMS serves pharmaceuticals and biotech, medical device, contract development manufacturing organizations, food and beverage, chemical and agrochemical, oil and gas, consumer goods, public health and clinical diagnostics organizations. In July 2021, private equity firm Francisco Partners acquired STARLIMS from Abbott.
By combining STARLIMS’ Laboratory Information Management System technology with Labstep’s SaaS ELN platform, users can remove complexity from the lab and unlock data’s true potential in a progressive, connected system. The acquisition of Labstep represents a significant milestone for STARLIMS, as it introduces a modern and user-friendly ELN to its existing platform.
